Clinical Trial Update: Phase Ib Trial of Two Virosome Formulated Malaria Vaccine Components (PEV 301, PEV 302) in Tanzania [Phase 1]

View source ↗

Summary

A Phase Ib/Phase 1 trial evaluating two virosome-formulated malaria vaccine components, PEV 301 and PEV 302, in Tanzania has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plasmodium Falciparum Malaria

Drugs mentioned

• PEV 301
• PEV 302

Snippet

Sponsor: Swiss Tropical & Public Health Institute | Conditions: Falciparum Malaria | Phase 1 | Status: COMPLETED